

# The influence of cocaine and cannabis on impulsivity.

Gepubliceerd: 01-12-2009 Laatst bijgewerkt: 18-08-2022

Acute challenges with cocaine and cannabis will induce two opposing dopaminergic states in the brain. Cocaine will stimulate dopamine release leading to hyperdopaminergia whereas cannabis will reduce central dopamine levels resulting in...

<b>Ethische beoordeling</b>	Niet van toepassing
<b>Status</b>	Werving nog niet gestart
<b>Type aandoening</b>	-
<b>Onderzoekstype</b>	Interventie onderzoek

## Samenvatting

### ID

NL-OMON25495

### Bron

Nationaal Trial Register

### Aandoening

cannabis  
cocaine  
impulsivity  
impulsiviteit  
genotypering  
genotyping  
dopamine  
COMT  
DBH

### Ondersteuning

**Primaire sponsor:** ZonMW

**Overige ondersteuning:** ZonMW

### Onderzoeksproduct en/of interventie

## **Uitkomstmaten**

### **Primaire uitkomstmaten**

The influence of cocaine and cannabis on impulsivity modulated by COMT and DBH genotypes. Genotyping of DBH will be performed before inclusion, COMT after testing.

## **Toelichting onderzoek**

### **Achtergrond van het onderzoek**

Genetic variations may affect drug induced changes in impulsivity and vulnerability to drug abuse. Two prime genes linking loss of impulse control, prefrontal dopamine (DA) and drug addiction are catechol O-methyltransferase (COMT) and dopamine beta-hydroxylase (DBH). Yet, the precise role of genetic variations on prefrontal DA and vulnerability to drug abuse is largely unknown. The current research proposal is designed to assess the influence of cocaine and cannabis on impulse control and to define the modulating role of the COMT and DBH genotypes on prefrontal DA and impulsive behaviours in cannabis and cocaine abusers. The research program consists of two major studies in regular users of cannabis and cocaine (N=60 in both studies) that will be conducted in parallel at Maastricht University and Radboud University Nijmegen Medical Centre. In each study, subjects will receive single doses of placebo, a THC dose of maximal 20mg and cocaine HCl 300mg according to a double blind, cross-over design. Impulsivity will be assessed objectively after administration of cannabis and cocaine with several performance models of impulse control (e.g. stop signal task, Cued Go/NoGo task) as well as with event related potentials and fMRI. Performance data will be analyzed separately for each centre but also combined in a meta-analysis over 120 subjects. It is expected that acute challenges with cocaine and cannabis will induce two opposing dopaminergic states in the brain. That is, cocaine will stimulate dopamine release leading to hyperdopaminergia whereas cannabis will reduce central dopamine levels resulting in hypodopaminergia. At present the common assumption is that a state of hypodopaminergia will lead to an increase in impulsive and risky behaviours such as drug use. Yet, the present studies are expected to demonstrate that drug induced impulsive behaviours can occur during both dopaminergic states depending on COMT and DBH genotypes and type of drug.

### **Doel van het onderzoek**

Acute challenges with cocaine and cannabis will induce two opposing dopaminergic states in the brain. Cocaine will stimulate dopamine release leading to hyperdopaminergia whereas cannabis will reduce central dopamine levels resulting in hypodopaminergia. Drug induced impulsive behaviours can occur during both dopaminergic states depending on COMT and DBH genotypes and type of drug.

## **Onderzoeksopzet**

Timepoint: 1 day.

## **Onderzoeksproduct en/of interventie**

1. Cocaine HCl 300mg as capsule;
2. Cannabis 20mg by inhalation;
3. Placebo.

## **Contactpersonen**

### **Publiek**

Postbus 616  
J. Wel, van  
Maastricht 6200 MD  
The Netherlands

### **Wetenschappelijk**

Postbus 616  
J. Wel, van  
Maastricht 6200 MD  
The Netherlands

## **Deelname eisen**

### **Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)**

1. Regular use of cannabis and cocaine;
2. Good physical and mental health;
3. Body weight between 80 and 130% of the ideal bodyweight as defined in the Metropolitan Life Insurance tables;

4. Age 18-40.

## **Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)**

1. Pregnancy or lactation;
2. Cardiovascular abnormalities as assessed by standard ECG;
3. Excessive drinking;
4. Hypertension;
5. History of psychiatric and neurological disorders.

## **Onderzoeksopzet**

### **Opzet**

Type:	Interventie onderzoek
Onderzoeksmodel:	Cross-over
Toewijzing:	N.v.t. / één studie arm
Blindering:	Dubbelblind
Controle:	Placebo

### **Deelname**

Nederland	
Status:	Werving nog niet gestart
(Verwachte) startdatum:	01-01-2010
Aantal proefpersonen:	60
Type:	Verwachte startdatum

## **Ethische beoordeling**

Niet van toepassing	
Soort:	Niet van toepassing

# Registraties

## Opgevolgd door onderstaande (mogelijk meer actuele) registratie

Geen registraties gevonden.

## Andere (mogelijk minder actuele) registraties in dit register

Geen registraties gevonden.

## In overige registers

Register	ID
NTR-new	NL2010
NTR-old	NTR2127
CCMO	NL29685.068.09
ISRCTN	ISRCTN wordt niet meer aangevraagd.

# Resultaten

## Samenvatting resultaten

N/A